Effect of tenofovir subtraction on HIV plasma viraemia, CD4 super(+) T-cell count and resistance in a patient with baseline K65R and M184V mutations

• Published in: Antiviral therapy Vol. 13; no. 5; pp. 735 - 737
• Main Authors: Hsu, R, Lanier, E R, Rouse, E G, Oie, K L, Pappa, KA, Ross, L L
• Format: Journal Article
• Language: English
• Published: 01-01-2008
• Subjects: Human immunodeficiency virus 1
• ISSN: 1359-6535

In vitro, the reverse transcriptase mutation K65R can simultaneously reduce drug susceptibility, replicative capacity and restrict HIV-1 replication. Here, we assessed the effect of tenofovir discontinuation for a patient receiving antiretroviral therapy whose HIV-1 had a dominant K65R/M184V genotype. Although limited by the single-case nature, the data support a hypothesis that there is no HIV viral RNA or CD4 super(+) T-cell count benefit of taking tenofovir for experienced patients with genotyplc evidence of K65R/M184V.